Luca Posa | Profiles RNS

Luca Posa, PharmD, PhD

Postdoctoral Associate

Boston University Chobanian & Avedisian School of Medicine

Pharmacology, Physiology & Biophysics

Pronouns: he/him/his

Websites

	LinkedIn
	Google Scholar
	ResearchGate

ORCID : 0000-0002-6464-1961

Dr. Posa's research focuses on pain and addiction in relationship with circadian rhythms. His goal is to improve the scientific knowledge on the pain sensitization process using behavioral studies, electrophysiology, optogenetics and neurochemistry. With strong analytical skills and knowledge in data analysis, Dr. Posa has a deep interest for the application of neuroscience to further understand the mechanisms of complex behaviors related to pain, reward, and motivation, at the intersection of circadian rhythms, and mood and substance use disorders.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Ji Y, Onwukwe C, Smith J, Laub H, Posa L, Keller A, Masri R, Cramer N. Noradrenergic Input from Nucleus of the Solitary Tract Regulates Parabrachial Activity in Mice. eNeuro. 2023 May; 10(5). PMID: 37072175; PMCID: PMC10162360; DOI: 10.1523/ENEURO.0412-22.2023;

Gamble MC, Williams BR, Singh N, Posa L, Freyberg Z, Logan RW, Puig S. Mu-opioid receptor and receptor tyrosine kinase crosstalk: Implications in mechanisms of opioid tolerance, reduced analgesia to neuropathic pain, dependence, and reward. Front Syst Neurosci. 2022; 16:1059089.View Related Profiles.

Posa, Luca
Puig, Stephanie

PMID: 36532632; PMCID: PMC9751598; DOI: 10.3389/fnsys.2022.1059089;

Rullo L, Caputi FF, Losapio LM, Morosini C, Posa L, Canistro D, Vivarelli F, Romualdi P, Candeletti S. Effects of Different Opioid Drugs on Oxidative Status and Proteasome Activity in SH-SY5Y Cells. Molecules. 2022 Nov 29; 27(23). PMID: 36500414; PMCID: PMC9738452; DOI: 10.3390/molecules27238321;

Posa L, De Gregorio D, Lopez-Canul M, He Q, Darcq E, Rullo L, Pearl-Dowler L, Luongo L, Candeletti S, Romualdi P, Kieffer BL, Gobbi G. Supraspinal melatonin MT2 receptor agonism alleviates pain via a neural circuit that recruits mu opioid receptors. J Pineal Res. 2022 Nov; 73(4):e12825. PMID: 35996205; DOI: 10.1111/jpi.12825;

Rullo L, Posa L, Caputi FF, Stamatakos S, Formaggio F, Caprini M, Liguori R, Candeletti S, Romualdi P. Nociceptive behavior and central neuropeptidergic dysregulations in male and female mice of a Fabry disease animal model. Brain Res Bull. 2021 Oct; 175:158-167. PMID: 34339779; DOI: 10.1016/j.brainresbull.2021.07.027;

De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, Posa L, Lopez-Canul M, Qianzi H, Lafferty CK, Britt JP, Comai S, Aguilar-Valles A, Sonenberg N, Gobbi G. Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. Proc Natl Acad Sci U S A. 2021 02 02; 118(5). PMID: 33495318; PMCID: PMC7865169; DOI: 10.1073/pnas.2020705118;

Caputi FF, Di Cesare Mannelli L, Rullo L, Micheli L, Stamatakos S, Posa L, Ghelardini C, Romualdi P, Candeletti S. The active second-generation proteasome inhibitor oprozomib reverts the oxaliplatin-induced neuropathy symptoms. Biochem Pharmacol. 2020 12; 182:114255. PMID: 33010214

De Gregorio D, Dean Conway J, Canul ML, Posa L, Bambico FR, Gobbi G. Effects of chronic exposure to low doses of ?9- tetrahydrocannabinol in adolescence and adulthood on serotonin/norepinephrine neurotransmission and emotional behaviors. Int J Neuropsychopharmacol. 2020 Jul 29; 23(11):751-61. PMID: 32725198; PMCID: PMC7745253; DOI: 10.1093/ijnp/pyaa058;

Posa L, Lopez-Canul M, Rullo L, De Gregorio D, Dominguez-Lopez S, Kaba Aboud M, Caputi FF, Candeletti S, Romualdi P, Gobbi G. Nociceptive responses in melatonin MT2 receptor knockout mice compared to MT1 and double MT1 /MT2 receptor knockout mice. J Pineal Res. 2020 Oct; 69(3):e12671. PMID: 32430930

Comai S, De Gregorio D, Posa L, Ochoa-Sanchez R, Bedini A, Gobbi G. Dysfunction of serotonergic activity and emotional responses across the light-dark cycle in mice lacking melatonin MT2 receptors. J Pineal Res. 2020 Aug; 69(1):e12653. PMID: 32239546

Showing 10 of 17 results. Show More

López-Canul M, Min SH, Posa L, De Gregorio D, Bedini A, Spadoni G, Gobbi G, Comai S. Melatonin MT1 and MT2 Receptors Exhibit Distinct Effects in the Modulation of Body Temperature across the Light/Dark Cycle. Int J Mol Sci. 2019 May 17; 20(10). PMID: 31108968; PMCID: PMC6566544; DOI: 10.3390/ijms20102452;

De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G. Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain. 2019 Jan; 160(1):136-150. PMID: 30157131; PMCID: PMC6319597; DOI: 10.1097/j.pain.0000000000001386;

De Gregorio D, Enns JP, Nuñez NA, Posa L, Gobbi G. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. Prog Brain Res. 2018; 242:69-96. PMID: 30471683

Posa L, De Gregorio D, Gobbi G, Comai S. Targeting Melatonin MT2 Receptors: A Novel Pharmacological Avenue for Inflammatory and Neuropathic Pain. Curr Med Chem. 2018; 25(32):3866-3882. PMID: 28183259

De Gregorio D, Comai S, Posa L, Gobbi G. d-Lysergic Acid Diethylamide (LSD) as a Model of Psychosis: Mechanism of Action and Pharmacology. Int J Mol Sci. 2016 Nov 23; 17(11). PMID: 27886063

De Gregorio D, Posa L, Ochoa-Sanchez R, McLaughlin R, Maione S, Comai S, Gobbi G. The hallucinogen d-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors. Pharmacol Res. 2016 11; 113(Pt A):81-91. PMID: 27544651

Posa L, Accarie A, Noble F, Marie N. Methadone Reverses Analgesic Tolerance Induced by Morphine Pretreatment. Int J Neuropsychopharmacol. 2016 07; 19(7). PMID: 26390873

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 17 publications over 7 distinct years, with a maximum of 4 publications in 2020